FZ 002
Alternative Names: FZ-002Latest Information Update: 25 Mar 2025
At a glance
- Originator Fzata
- Class Gene therapies
- Mechanism of Action Gastrointestinal microbiome modulators; Gene expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Clostridium difficile infections
Most Recent Events
- 11 Mar 2025 Fzata entered into a research and development agreement with National Institutes of Health for phase I trial of Clostridium difficile infections
- 07 May 2024 Fzata plans a phase I trial for Clostridium difficile infections in 4Q 2024
- 07 May 2024 Fzata plans to file an IND application for Clostridium difficile infections in 3Q 2024